Establishment of hemophilia A patient-specific inducible pluripotent stem cells with urine cells.
10.3760/cma.j.issn.1003-9406.2015.05.001
- Author:
Zhiqing HU
1
;
Xuyun HU
;
Jialun PANG
;
Xiaolin WANG
;
Siyuan Lin PENG
;
Zhuo LI
;
Yong WU
;
Lingqian WU
;
Desheng LIANG
Author Information
1. State Key Laboratory of Medical Genetics, Central South University, Changsha, Hunan 410078, P.R. China. Email: liangdesheng@sklmg.edu.cn.
- Publication Type:Journal Article
- MeSH:
Cell Differentiation;
Hemophilia A;
pathology;
therapy;
urine;
Humans;
Induced Pluripotent Stem Cells;
cytology;
transplantation;
Urine;
cytology
- From:
Chinese Journal of Medical Genetics
2015;32(5):609-614
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To generate hemophilia A (HA) patient-specific inducible pluripotent stem cells (iPSCs) and induce endothelial differentiation. METHODS Tubular epithelial cells were isolated and cultured from the urine of HA patients. The iPSCs were generated by forced expression of Yamanaka factors (Oct4, Sox2, c-Myc and Klf4) using retroviruses and characterized by cell morphology, pluripotent marker staining and in vivo differentiation through teratoma formation. Induced endothelial differentiation of the iPSCs was achieved with the OP9 cell co-culture method. RESULTS Patient-specific iPSCs were generated from urine cells of the HA patients, which could be identified by cell morphology, pluripotent stem cell surface marker staining and in vivo differentiation of three germ layers. The teratoma experiment has confirmed that such cells could differentiate into endothelial cells expressing the endothelial-specific markers CD144, CD31 and vWF. CONCLUSION HA patient-specific iPSCs could be generated from urine cells and can differentiate into endothelial cells. This has provided a new HA disease modeling approach and may serve as an applicable autologous cell source for gene correction and cell therapy studies for HA.
